{
  "ticker": "ADMA",
  "company_name": "ADMA Biologics Inc",
  "success": true,
  "trials": [
    {
      "nct_id": "NCT00538915",
      "title": "Open Label, Phase III Study of NABI-IGIV 10% [Immune Globulin Intravenous(Human), 10%] In Subjects With Primary Immune Deficiency Disorders (PIDD)",
      "status": "COMPLETED",
      "phase": "PHASE3",
      "condition": "Primary Immune Deficiency Disorders (PIDD)",
      "start_date": "2007-09",
      "completion_date": "2009-07",
      "enrollment": 0,
      "sponsor": "ADMA Biologics, Inc."
    },
    {
      "nct_id": "NCT00473824",
      "title": "Randomized Phase II Study of Hepatitis C Immune Globulin Intravenous (Human), Civacir(TM), in Liver Transplantation",
      "status": "TERMINATED",
      "phase": "PHASE2",
      "condition": "Sequelae of Viral Hepatitis, Transplantation Infection, Evidence of Liver Transplantation",
      "start_date": "2007-05",
      "completion_date": "2009-02",
      "enrollment": 0,
      "sponsor": "ADMA Biologics, Inc."
    },
    {
      "nct_id": "NCT03164967",
      "title": "Study to Evaluate Safety and Pharmacokinetics of BIVIGAM\u00ae in Primary Immune Deficiency Subjects Aged 2 to 16",
      "status": "COMPLETED",
      "phase": "PHASE4",
      "condition": "Humoral Immune Response",
      "start_date": "2016-12-29",
      "completion_date": "2022-12-31",
      "enrollment": 0,
      "sponsor": "ADMA Biologics, Inc."
    },
    {
      "nct_id": "NCT03037359",
      "title": "A Study About Low Blood Pressure in Patients With Primary Immunodeficiency Disease Treated With Immune Globulin Products",
      "status": "UNKNOWN",
      "phase": "",
      "condition": "Primary Immune Deficiency Disorder",
      "start_date": "2016-12",
      "completion_date": "2023-06-30",
      "enrollment": 0,
      "sponsor": "ADMA Biologics, Inc."
    },
    {
      "nct_id": "NCT00632463",
      "title": "RI-001 in Immunosuppressed Respiratory Syncytial Virus (RSV) Infected Patients at Risk of Lower Tract RSV Illness",
      "status": "COMPLETED",
      "phase": "PHASE2",
      "condition": "Upper Respiratory Tract Infection, Lower Respiratory Tract Infection",
      "start_date": "2008-02",
      "completion_date": "2010-05",
      "enrollment": 0,
      "sponsor": "ADMA Biologics, Inc."
    },
    {
      "nct_id": "NCT01814800",
      "title": "Pharmacokinetics, Efficacy, and Safety Study of RI-002 (IGIV) in Subjects With Primary Immunodeficiency Diseases (PIDD)",
      "status": "COMPLETED",
      "phase": "PHASE3",
      "condition": "Primary Immune Deficiency Disorder",
      "start_date": "2014-02",
      "completion_date": "2015-01",
      "enrollment": 0,
      "sponsor": "ADMA Biologics, Inc."
    },
    {
      "nct_id": "NCT05070455",
      "title": "An Open Label, Multicenter Study to Evaluate the Pharmacokinetics, Efficacy and Safety of ASCENIV\u2122 (IGIV) in Pediatric Subjects With Primary Immunodeficiency Diseases (PIDD)",
      "status": "UNKNOWN",
      "phase": "PHASE4",
      "condition": "Primary Immune Deficiency",
      "start_date": "2022-09-01",
      "completion_date": "2023-06-30",
      "enrollment": 0,
      "sponsor": "ADMA Biologics, Inc."
    }
  ],
  "summary": {
    "total_trials": 7,
    "by_phase": {
      "PHASE3": 2,
      "PHASE2": 2,
      "PHASE4": 2,
      "": 1
    },
    "by_status": {
      "COMPLETED": 4,
      "TERMINATED": 1,
      "UNKNOWN": 2
    },
    "active_trials": 0,
    "completed_trials": 4,
    "conditions": [
      "Humoral Immune Response",
      "Primary Immune Deficiency",
      "Primary Immune Deficiency Disorder",
      "Primary Immune Deficiency Disorders (PIDD)",
      "Sequelae of Viral Hepatitis, Transplantation Infection, Evidence of Liver Transplantation",
      "Upper Respiratory Tract Infection, Lower Respiratory Tract Infection"
    ],
    "lead_stage": "commercial"
  },
  "provenance": {
    "source": "ClinicalTrials.gov API v2",
    "timestamp": "2026-01-29T12:16:03.589685",
    "search_query": "ADMA Biologics Inc",
    "url": "https://clinicaltrials.gov/search?term=ADMA+Biologics+Inc"
  }
}